194 related articles for article (PubMed ID: 16189079)
1. Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor.
Ferris RG; Hazen RJ; Roberts GB; St Clair MH; Chan JH; Romines KR; Freeman GA; Tidwell JH; Schaller LT; Cowan JR; Short SA; Weaver KL; Selleseth DW; Moniri KR; Boone LR
Antimicrob Agents Chemother; 2005 Oct; 49(10):4046-51. PubMed ID: 16189079
[TBL] [Abstract][Full Text] [Related]
2. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.
Hazen RJ; Harvey RJ; St Clair MH; Ferris RG; Freeman GA; Tidwell JH; Schaller LT; Cowan JR; Short SA; Romines KR; Chan JH; Boone LR
Antimicrob Agents Chemother; 2005 Nov; 49(11):4465-73. PubMed ID: 16251284
[TBL] [Abstract][Full Text] [Related]
3. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
4. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
Romines KR; Freeman GA; Schaller LT; Cowan JR; Gonzales SS; Tidwell JH; Andrews CW; Stammers DK; Hazen RJ; Ferris RG; Short SA; Chan JH; Boone LR
J Med Chem; 2006 Jan; 49(2):727-39. PubMed ID: 16420058
[TBL] [Abstract][Full Text] [Related]
6. In vitro resistance development for RO-0335, a novel diphenylether nonnucleoside reverse transcriptase inhibitor.
Javanbakht H; Ptak RG; Chow E; Yan JM; Russell JD; Mankowski MK; Hogan PA; Hogg JH; Vora H; Hang JQ; Li Y; Su G; Paul A; Cammack N; Klumpp K; Heilek G
Antiviral Res; 2010 May; 86(2):212-9. PubMed ID: 20219553
[TBL] [Abstract][Full Text] [Related]
7. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
Andries K; Azijn H; Thielemans T; Ludovici D; Kukla M; Heeres J; Janssen P; De Corte B; Vingerhoets J; Pauwels R; de Béthune MP
Antimicrob Agents Chemother; 2004 Dec; 48(12):4680-6. PubMed ID: 15561844
[TBL] [Abstract][Full Text] [Related]
8. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
9. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
10. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
[TBL] [Abstract][Full Text] [Related]
11. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
[TBL] [Abstract][Full Text] [Related]
12. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
13. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
Soulie C; Santoro MM; Storto A; Abdi B; Charpentier C; Armenia D; Jary A; Forbici F; Bertoli A; Gennari W; Andreoni M; Mussini C; Antinori A; Perno CF; Calvez V; Ceccherini-Silberstein F; Descamps D; Marcelin AG
J Antimicrob Chemother; 2020 Apr; 75(4):1026-1030. PubMed ID: 31976534
[TBL] [Abstract][Full Text] [Related]
15. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
[TBL] [Abstract][Full Text] [Related]
16. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
[TBL] [Abstract][Full Text] [Related]
17. Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
Cywin CL; Klunder JM; Hoermann M; Brickwood JR; David E; Grob PM; Schwartz R; Pauletti D; Barringer KJ; Shih CK; Sorge CL; Erickson DA; Joseph DP; Hattox SE
J Med Chem; 1998 Jul; 41(16):2972-84. PubMed ID: 9685236
[TBL] [Abstract][Full Text] [Related]
18. 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Rao A; Balzarini J; Carbone A; Chimirri A; De Clercq E; Monforte AM; Monforte P; Pannecouque C; Zappalà M
Antiviral Res; 2004 Aug; 63(2):79-84. PubMed ID: 15302136
[TBL] [Abstract][Full Text] [Related]
19. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]